• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry
Conclusions Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Chieffo, A., Petronio, A. S., Mehilli, J., Chandrasekhar, J., Sartori, S., Lefevre, T., Presbitero, P., Capranzano, P., Tchetche, D., Iadanza, A., Sardella, G., Van Mieghem, N. M., Meliga, E., Dumonteil, N., Fraccaro, C., Trabattoni, D., Mikhail, G., Shar Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research

Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
CONCLUSIONS: The AVIATOR 2 study is the first digital health study examining physician-patient perspectives on ATT choices after AF-PCI. TT was the most common strategy without differences in 1-year outcomes in ATT strategy. Physicians rated safety first when prescribing ATT; patients feared stroke over bleeding.CLINICALTRIALS: gov: NCT02362659.PMID:35656720 | DOI:10.4244/EIJ-D-21-01044
Source: EuroIntervention - June 3, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Jaya Chandrasekhar Usman Baber Samantha Sartori Ridhima Goel Johny Nicolas Birgit Vogel Clayton Snyder Annapoorna Kini Carlo Briguori Bernhard Witzenbichler Ioannis Iakovou Gennaro Sardella Kevin Marzo Anthony DeFranco Thomas Stuckey Alaide Chieffo Antoni Source Type: research

Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy The SECURITY Randomized Clinical Trial
BackgroundThe optimal duration of dual antiplatelet therapy (DAPT) following second-generation drug-eluting stent (DES) implantation is still debated.ObjectivesThe aim of this study was to test the noninferiority of 6 versus 12 months of DAPT in patients undergoing percutaneous coronary intervention with second-generation DES.MethodsThe SECURITY (Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy) trial was a 1:1 randomized, multicenter, international, investigator-driven, noninferiority study conducted from July 2009 to June 2014. Patients with a stable or unst...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - November 10, 2014 Category: Cardiology Source Type: research

Coronary Stent Thrombosis With Vorapaxar Versus Placebo Results From the TRA 2°P-TIMI 50 Trial
BackgroundVorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease.ObjectivesThe goal of this study was to test the hypothesis that treatment with vorapaxar reduces the rate of coronary stent thrombosis (ST) in stable patients with a history of coronary stenting.MethodsTRA 2°P-TIMI 50 (Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a multinational, randomized, d...
Source: Journal of the American College of Cardiology - December 1, 2014 Category: Cardiology Source Type: research

Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial
ConclusionsClinically relevant bleeding events were observed in one out of five elderly patients undergoing stenting for an ACS and were strongly associated with further stroke occurrence. Rather than the antiplatelet therapy, comorbidities and an age>  85 years predicted bleeding outcomes in this elderly population.Clinical Trial RegistrationClinicaltrials.gov identifier: NCT01538446.https://www.clinicaltrials.gov.
Source: American Journal of Cardiovascular Drugs - June 30, 2021 Category: Cardiology Source Type: research

Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
CONCLUSION: Chinese patients with AF and coronary stenting had high mortality and incidence of MACCE. We compiled separate predictive models for all-cause death, IS/STE, MACCE, and major bleeding.PMID:34353224 | DOI:10.1080/00015385.2021.1950367
Source: Acta Cardiologica - August 6, 2021 Category: Cardiology Authors: Jian-Yong Zheng Yi Cao Dong-Tao Li Yi-Gang Qiu Li Zhao Zheng-Ming Xu Yi-Xiong Huang Zhi-Bo Hong Tian-Chang Li Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yu Chen Source Type: research

Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.PMID:35979636 | DOI:10.4244/EIJ-D-22-00319
Source: EuroIntervention - August 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Gennaro Sardella Frans J Beerkens George Dangas Davide Cao Usman Baber Samantha Sartori David J Cohen Carlo Briguori Robert Gil Johny Nicolas Zhongjie Zhang Dariusz Dudek Vijay Kunadian Ran Kornowski Giora Weisz Bimmer Claessen Steven O Marx Javier Escane Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16